MX370664B - Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. - Google Patents

Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.

Info

Publication number
MX370664B
MX370664B MX2016002077A MX2016002077A MX370664B MX 370664 B MX370664 B MX 370664B MX 2016002077 A MX2016002077 A MX 2016002077A MX 2016002077 A MX2016002077 A MX 2016002077A MX 370664 B MX370664 B MX 370664B
Authority
MX
Mexico
Prior art keywords
grp94 inhibitors
selective grp94
compounds
effective amount
selective
Prior art date
Application number
MX2016002077A
Other languages
English (en)
Other versions
MX2016002077A (es
Inventor
Sun Weilin
Taldone Tony
Patel Pallav
Chiosis Gabriela
Yan Pengrong
J Patel Hardik
Yang Chenghua
O Ochiana Stefan
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2016002077A publication Critical patent/MX2016002077A/es
Publication of MX370664B publication Critical patent/MX370664B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Computing Systems (AREA)
  • Library & Information Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)

Abstract

La descripción se refiere a inhibidores de Gpr94 selectivos novedosos, a composiciones que comprenden una cantidad eficaz de tales compuestos, y a métodos para tratar o prevenir una condición, tal como cáncer, que comprende administrar a un animal que lo necesita una cantidad eficaz de tales compuestos.
MX2016002077A 2013-08-16 2014-08-15 Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. MX370664B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361866932P 2013-08-16 2013-08-16
PCT/US2014/051332 WO2015023976A2 (en) 2013-08-16 2014-08-15 Selective grp94 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
MX2016002077A MX2016002077A (es) 2016-07-21
MX370664B true MX370664B (es) 2019-12-19

Family

ID=52468819

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002077A MX370664B (es) 2013-08-16 2014-08-15 Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.

Country Status (17)

Country Link
US (3) US10421758B2 (es)
EP (1) EP3033338A4 (es)
JP (2) JP6539275B2 (es)
KR (1) KR102319582B1 (es)
CN (1) CN105899503B (es)
AU (2) AU2014306417C1 (es)
BR (1) BR112016003201A2 (es)
CA (1) CA2921571C (es)
EA (1) EA201690406A1 (es)
HK (1) HK1226063A1 (es)
IL (2) IL244251B (es)
MX (1) MX370664B (es)
PH (1) PH12016500511A1 (es)
SG (2) SG10201801281QA (es)
TW (1) TWI711618B (es)
WO (1) WO2015023976A2 (es)
ZA (1) ZA201601794B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
AU2007269144B2 (en) 2006-06-30 2013-05-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
ES2733131T3 (es) 2009-10-07 2019-11-27 Sloan Kettering Inst Cancer Res Derivados de purina útiles como inhibidores de hsp90
CN103582642B (zh) 2011-04-05 2021-05-11 索隆-基特林癌症研究协会 Hsp90抑制剂
EA024647B1 (ru) 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
CN105637097A (zh) * 2013-08-05 2016-06-01 特韦斯特生物科学公司 从头合成的基因文库
AU2014306417C1 (en) * 2013-08-16 2019-07-25 Memorial Sloan-Kettering Cancer Center Selective Grp94 inhibitors and uses thereof
RU2016128528A (ru) 2013-12-23 2018-01-30 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Способы и реактивы для введения радиоактивной метки
CN107110869B (zh) 2014-09-17 2021-08-10 纪念斯隆-凯特琳癌症中心 Hsp90-靶向炎症和感染成像及治疗
KR20180058824A (ko) 2015-10-05 2018-06-01 메모리얼 슬로안-케터링 캔서 센터 암 치료를 위한 합리적 병용 요법
CN108503643B (zh) * 2017-02-28 2020-09-15 泉州易初生物医药科技有限公司 蛋白酶抑制剂的制备方法
US11260132B2 (en) * 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
WO2019136093A1 (en) * 2018-01-02 2019-07-11 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
US11774451B2 (en) * 2019-11-21 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University Molecular vibrational spectroscopic markers for detection of cancer
WO2021251564A1 (ko) * 2020-06-09 2021-12-16 국민대학교산학협력단 Grp94에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편 및 이들의 용도
KR20230000050A (ko) 2021-06-24 2023-01-02 최현지 페이크 마스크
CN113663078B (zh) * 2021-06-28 2023-05-16 四川大学 Grp94抑制剂在制备治疗EGFR驱动的癌症的药物中的用途
KR20240012846A (ko) 2022-07-21 2024-01-30 성균관대학교산학협력단 신규한 hdac6 선택적 억제제 및 이의 용도
CN115717144A (zh) * 2022-08-25 2023-02-28 南通市肿瘤医院 抑制hsp90b1表达的小干扰rna及其在膀胱癌衰老中的应用
WO2024059745A2 (en) * 2022-09-15 2024-03-21 Bexson Biomedical, Inc. N-methyl-d-aspartate receptor (nmdar) antagonists and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU681687B2 (en) 1993-07-15 1997-09-04 Minnesota Mining And Manufacturing Company Imidazo(4,5-c)pyridin-4-amines
US7439359B2 (en) 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
EP2336133A1 (en) 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
WO2003041643A2 (en) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
AU2006331917A1 (en) 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
EP2038041A4 (en) 2006-05-12 2010-02-17 Myriad Genetics Inc THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
AU2007269144B2 (en) 2006-06-30 2013-05-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
EP2069794A1 (en) * 2006-10-03 2009-06-17 University of Southern California Grp78 as a predictor of responsiveness to therapeutic agents
WO2008115719A1 (en) * 2007-03-20 2008-09-25 Curis, Inc. Fused amino pyridine as hsp90 inhibitors
JP2011503206A (ja) 2007-11-14 2011-01-27 ミレクシス， インコーポレイテッド 疾患および障害の治療における治療化合物およびその使用方法
WO2010042500A2 (en) 2008-10-06 2010-04-15 Emory University Heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
ES2733131T3 (es) 2009-10-07 2019-11-27 Sloan Kettering Inst Cancer Res Derivados de purina útiles como inhibidores de hsp90
EA024647B1 (ru) 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
CN103582642B (zh) 2011-04-05 2021-05-11 索隆-基特林癌症研究协会 Hsp90抑制剂
US8685966B2 (en) * 2011-04-08 2014-04-01 University Of Kansas GRP94 inhibitors
EP2714081A4 (en) 2011-05-27 2015-09-09 Cytocure Llc METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
JP6054389B2 (ja) 2011-07-08 2016-12-27 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 標識されたｈｓｐ９０阻害剤の使用
AU2014306417C1 (en) 2013-08-16 2019-07-25 Memorial Sloan-Kettering Cancer Center Selective Grp94 inhibitors and uses thereof

Also Published As

Publication number Publication date
MX2016002077A (es) 2016-07-21
TW201516047A (zh) 2015-05-01
JP2019178147A (ja) 2019-10-17
AU2014306417B2 (en) 2019-01-17
SG11201601542SA (en) 2016-04-28
IL267681B2 (en) 2023-03-01
EP3033338A4 (en) 2017-06-14
KR102319582B1 (ko) 2021-11-04
CN105899503A (zh) 2016-08-24
JP2016533384A (ja) 2016-10-27
US20200102312A1 (en) 2020-04-02
PH12016500511A1 (en) 2016-06-13
US10421758B2 (en) 2019-09-24
AU2014306417A1 (en) 2016-03-17
AU2019202669B2 (en) 2020-12-03
CN105899503B (zh) 2020-08-18
TWI711618B (zh) 2020-12-01
CA2921571C (en) 2022-04-05
AU2019202669A1 (en) 2019-05-09
JP6848009B2 (ja) 2021-03-24
SG10201801281QA (en) 2018-04-27
US11267816B2 (en) 2022-03-08
AU2014306417C1 (en) 2019-07-25
ZA201601794B (en) 2019-09-25
IL244251A0 (en) 2016-04-21
CA2921571A1 (en) 2015-02-19
JP6539275B2 (ja) 2019-07-03
BR112016003201A2 (pt) 2017-11-21
US20160194328A1 (en) 2016-07-07
EP3033338A2 (en) 2016-06-22
WO2015023976A2 (en) 2015-02-19
IL267681B (en) 2022-11-01
KR20160043534A (ko) 2016-04-21
US20230123747A1 (en) 2023-04-20
HK1226063A1 (zh) 2017-09-22
IL244251B (en) 2019-07-31
WO2015023976A3 (en) 2015-04-23
IL267681A (en) 2019-08-29
EA201690406A1 (ru) 2016-08-31

Similar Documents

Publication Publication Date Title
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX2015011897A (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2019002259A (es) Inhibicion de la actividad de la olig2.
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
AU2014353885A8 (en) Prevention and treatment of toxicosis
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
PH12020500472A1 (en) Autotaxin inhibitor compounds
EA201691907A1 (ru) Комбинированная терапия кураксинами

Legal Events

Date Code Title Description
FG Grant or registration